Studies of TGEV Spike Protein Gp195 Expressed in E. Coli and by a TGE-Vaccinia Virus Recombinant
- 1 January 1985
- book chapter
- Published by Springer Nature
- Vol. 185, 63-82
- https://doi.org/10.1007/978-1-4684-7974-4_4
Abstract
The gene coding for the surface spike protein gp195 of TGEV has been cloned and expressed in E. coli in the form of fusion proteins. These proteins were isolated and used to immunize laboratory animals. All animals developed antibodies cross-reacting with the TGEV virion but failed to neutralize the virus. The entire gp195 gene was also inserted into vaccinia to generate a TGEV-vaccinia recombinant virus (vTGE) that expressed TGEV gp195. Animals vaccinated with vTGE produced neutralizing antibodies against both TGEV and vaccinia. These results suggest the potential use of the recombinant vTGE as a vaccine against TGEV infection.Keywords
This publication has 10 references indexed in Scilit:
- Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.Proceedings of the National Academy of Sciences, 1984
- Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.Proceedings of the National Academy of Sciences, 1983
- Monoclonal antibodies to murine hepatitis virus-4 (strain JHM) define the viral glycoprotein responsible for attachment and cell-cell fusionVirology, 1982
- Tunicamycin resistant glycosylation of a coronavirus glycoprotein: Demonstration of a novel type of viral glycoproteinVirology, 1981
- Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src).Proceedings of the National Academy of Sciences, 1979
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970